{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:58:33Z","timestamp":1790834313815,"version":"4.1.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.3109\/14653249.2012.671519","type":"journal-article","created":{"date-parts":[[2012,3,29]],"date-time":"2012-03-29T09:39:00Z","timestamp":1333013940000},"page":"830-840","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":161,"title":["A clinically adaptable method to enhance the cytotoxicity of natural killer cells against B-cell malignancies"],"prefix":"10.1016","volume":"14","author":[{"given":"Noriko","family":"Shimasaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Fujisaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duck","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marika","family":"Masselli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Lockey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Eldridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wing","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Campana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.3109\/14653249.2012.671519_bib0005","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1126\/science.1068440","article-title":"Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants","volume":"295","author":"Ruggeri","year":"2002","journal-title":"Science"},{"key":"10.3109\/14653249.2012.671519_bib0010","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1126\/science.1198687","article-title":"Innate or adaptive immunity? The example of natural killer cells","volume":"331","author":"Vivier","year":"2011","journal-title":"Science"},{"key":"10.3109\/14653249.2012.671519_bib0015","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1182\/blood-2010-08-264085","article-title":"Killer Ig-like receptor-mediated control of natural killer cell alloreactivity in haploidentical hematopoietic stem cell transplantation","volume":"117","author":"Moretta","year":"2011","journal-title":"Blood"},{"key":"10.3109\/14653249.2012.671519_bib0020","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1182\/blood.V94.1.333.413a31_333_339","article-title":"Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation","volume":"94","author":"Ruggeri","year":"1999","journal-title":"Blood"},{"key":"10.3109\/14653249.2012.671519_bib0025","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1182\/blood-2003-01-0091","article-title":"Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors","volume":"102","author":"Giebel","year":"2003","journal-title":"Blood"},{"key":"10.3109\/14653249.2012.671519_bib0030","doi-asserted-by":"crossref","first-page":"4878","DOI":"10.1182\/blood-2004-12-4825","article-title":"Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes","volume":"105","author":"Hsu","year":"2005","journal-title":"Blood"},{"key":"10.3109\/14653249.2012.671519_bib0035","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1182\/blood-2010-05-283051","article-title":"Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia","volume":"116","author":"Cooley","year":"2010","journal-title":"Blood"},{"key":"10.3109\/14653249.2012.671519_bib0040","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1182\/blood-2004-07-2974","article-title":"Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in cancer patients","volume":"105","author":"Miller","year":"2005","journal-title":"Blood"},{"key":"10.3109\/14653249.2012.671519_bib0045","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1200\/JCO.2009.24.4590","article-title":"NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia","volume":"28","author":"Rubnitz","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.3109\/14653249.2012.671519_bib0050","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/j.bbmt.2010.03.004","article-title":"Donor KIR genes 2DL5A, 2DS1 and 3DS1 are associated with a reduced rate of leukemia relapse after HLA-identical sibling stem cell transplantation for acute myeloid leukemia but not other hematologic malignancies","volume":"16","author":"Stringaris","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.3109\/14653249.2012.671519_bib0055","doi-asserted-by":"crossref","first-page":"644","DOI":"10.4049\/jimmunol.172.1.644","article-title":"Determinants of antileukemia effects of allogeneic NK cells","volume":"172","author":"Leung","year":"2004","journal-title":"J Immunol"},{"key":"10.3109\/14653249.2012.671519_bib0060","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1182\/blood-2008-06-164103","article-title":"Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity","volume":"113","author":"Pende","year":"2009","journal-title":"Blood"},{"key":"10.3109\/14653249.2012.671519_bib0065","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.3324\/haematol.2009.021121","article-title":"Reconstitution of natural killer cell receptors influences natural killer activity and relapse rate after haploidentical transplantation of T- and B-cell depleted grafts in children","volume":"95","author":"Pfeiffer","year":"2010","journal-title":"Haematologica"},{"key":"10.3109\/14653249.2012.671519_bib0070","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1158\/0008-5472.CAN-10-3326","article-title":"Natural killer cells efficiently reject lymphoma silenced for the endoplasmic reticulum aminopeptidase associated with antigen processing","volume":"71","author":"Cifaldi","year":"2011","journal-title":"Cancer Res"},{"key":"10.3109\/14653249.2012.671519_bib0075","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1182\/blood-2004-12-4797","article-title":"Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells","volume":"106","author":"Imai","year":"2005","journal-title":"Blood"},{"key":"10.3109\/14653249.2012.671519_bib0080","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1182\/blood.V83.7.1731.1731","article-title":"Interleukin-4 induces programmed cell death (apoptosis) in cases of high-risk acute lymphoblastic leukemia","volume":"83","author":"Manabe","year":"1994","journal-title":"Blood"},{"key":"10.3109\/14653249.2012.671519_bib0085","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/jcp.1040980203","article-title":"Dexamethasone induces irreversible G1 arrest and death of a human lymphoid cell line","volume":"98","author":"Harmon","year":"1979","journal-title":"J Cell Physiol"},{"key":"10.3109\/14653249.2012.671519_bib0090","doi-asserted-by":"crossref","first-page":"4010","DOI":"10.1158\/0008-5472.CAN-08-3712","article-title":"Expansion of highly cytotoxic human natural killer cells for cancer cell therapy","volume":"69","author":"Fujisaki","year":"2009","journal-title":"Cancer Res"},{"key":"10.3109\/14653249.2012.671519_bib0095","first-page":"4010","article-title":"Replicative potential of human natural killer cells","volume":"69","author":"Fujisaki","year":"2009","journal-title":"Br J Haematol"},{"key":"10.3109\/14653249.2012.671519_bib0100","doi-asserted-by":"crossref","first-page":"3901","DOI":"10.1158\/1078-0432.CCR-10-0735","article-title":"Cytotoxicity of activated natural killer cells against pediatric solid tumors","volume":"16","author":"Cho","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.3109\/14653249.2012.671519_bib0105","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/sj.leu.2403302","article-title":"Chimeric receptors with 4 - 1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia","volume":"18","author":"Imai","year":"2004","journal-title":"Leukemia"},{"key":"10.3109\/14653249.2012.671519_bib0110","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/cgt.2009.61","article-title":"Expression of chimeric antigen receptors in natural killer cells with a regulatory-compliant non-viral method","volume":"17","author":"Li","year":"2010","journal-title":"Cancer Gene Ther"},{"key":"10.3109\/14653249.2012.671519_bib0115","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1046\/j.1365-2141.2003.04217.x","article-title":"Development and functional characterization of human bone marrow mesenchymal cells immortalized by enforced expression of telomerase","volume":"120","author":"Mihara","year":"2003","journal-title":"Br J Haematol"},{"key":"10.3109\/14653249.2012.671519_bib0120","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1006\/cimm.1998.1396","article-title":"NK1.1 cells express 4 - 1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4 - 1BB monoclonal antibodies","volume":"190","author":"Melero","year":"1998","journal-title":"Cell Immunol"},{"key":"10.3109\/14653249.2012.671519_bib0125","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1182\/blood-2010-08-301945","article-title":"CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies","volume":"117","author":"Kohrt","year":"2011","journal-title":"Blood"},{"key":"10.3109\/14653249.2012.671519_bib0130","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.semcancer.2010.06.003","article-title":"The genomic risk of somatic gene therapy","volume":"20","author":"Kustikova","year":"2010","journal-title":"Semin Cancer Biol"},{"key":"10.3109\/14653249.2012.671519_bib0135","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nrc971","article-title":"Targeting tumours with genetically enhanced T lymphocytes","volume":"3","author":"Sadelain","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"10.3109\/14653249.2012.671519_bib0140","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/nrc2355","article-title":"Adoptive cell transfer: a clinical path to effective cancer immunotherapy","volume":"8","author":"Rosenberg","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"10.3109\/14653249.2012.671519_bib0145","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1038\/nri2635","article-title":"Engineering lymphocyte subsets: tools, trials and tribulations","volume":"9","author":"June","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"10.3109\/14653249.2012.671519_bib0150","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.coi.2010.01.020","article-title":"Adoptive T cell therapy of cancer","volume":"22","author":"Brenner","year":"2010","journal-title":"Curr Opin Immunol"},{"key":"10.3109\/14653249.2012.671519_bib0155","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N Engl J Med"},{"key":"10.3109\/14653249.2012.671519_bib0160","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1089\/hum.2006.17.1027","article-title":"Synthetic messenger RNA as a tool for gene therapy","volume":"17","author":"Rabinovich","year":"2006","journal-title":"Hum Gene Ther"},{"key":"10.3109\/14653249.2012.671519_bib0165","doi-asserted-by":"crossref","first-page":"9053","DOI":"10.1158\/0008-5472.CAN-10-2880","article-title":"Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor","volume":"70","author":"Zhao","year":"2010","journal-title":"Cancer Res"},{"key":"10.3109\/14653249.2012.671519_bib0170","doi-asserted-by":"crossref","first-page":"9554","DOI":"10.1158\/0008-5472.CAN-10-2211","article-title":"Genotypes of NK cell KIR receptors, their ligands, and Fcgamma receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy","volume":"70","author":"Delgado","year":"2010","journal-title":"Cancer Res"},{"key":"10.3109\/14653249.2012.671519_bib0175","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1056\/NEJMoa0900386","article-title":"Treating childhood acute lymphoblastic leukemia without cranial irradiation","volume":"360","author":"Pui","year":"2009","journal-title":"N Engl J Med"},{"key":"10.3109\/14653249.2012.671519_bib0180","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1002\/cncr.24862","article-title":"Adult acute lymphoblastic leukemia: concepts and strategies","volume":"116","author":"Faderl","year":"2010","journal-title":"Cancer"},{"key":"10.3109\/14653249.2012.671519_bib0185","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1200\/JCO.2010.32.3865","article-title":"Update on therapy of chronic lymphocytic leukemia","volume":"29","author":"Gribben","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.3109\/14653249.2012.671519_bib0190","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1001\/archinternmed.2007.125","article-title":"Ongoing improvement in outcomes for patients diagnosed as having non-Hodgkin lymphoma from the 1990s to the early 21st century","volume":"168","author":"Pulte","year":"2008","journal-title":"Arch Intern Med"},{"key":"10.3109\/14653249.2012.671519_bib0195","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0022-1759(00)00228-3","article-title":"Immunophenotyping of leukemia","volume":"243","author":"Campana","year":"2000","journal-title":"J Immunol Methods"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324912706989?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324912706989?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T22:17:05Z","timestamp":1761430625000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324912706989"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8]]},"references-count":39,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["S1465324912706989"],"URL":"https:\/\/doi.org\/10.3109\/14653249.2012.671519","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2012,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A clinically adaptable method to enhance the cytotoxicity of natural killer cells against B-cell malignancies","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.3109\/14653249.2012.671519","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 International Society for Cellular Therapy. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}